Zunsemetinib · ATI-450, CDD-450

What is Zunsemetinib?

Zunsemetinib is an orally bioavailable small molecule inhibitor of the p38MAPK-MK2 complex. It inhibits p38MAPK phosphorylation and MK2 activation, suppressing p38MAPK/MK2-mediated inflammatory signaling and reducing production of proinflammatory cytokines including TNF-alpha, IL-1-alpha, IL-1-beta, and IL-6. It is studied in metastatic breast cancer, pancreatic cancer, hidradenitis suppurativa, and rheumatoid arthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

ATI-450, CDD-450, Zumsemetinib

Drug type

Small molecule

Targets

MAPKAPK2, p38MAPK (MAPK14)

Mechanism

Inhibitor of MAPKAPK2 and p38MAPK (MAPK14)

Pathways

p38MAPK/MK2 signaling, inflammatory cytokine production

Therapy area

Immunology, Musculoskeletal, Oncology

Developer

Aclaris Therapeutics, Inc. (ACRS)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 2

UNII

AX2VWG0ZCR

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cancer of the PancreasMetastatic Pancreatic Ductal AdenocarcinomaPancreatic CancerHidradenitis SuppurativaRheumatoid Arthritis

Other drugs acting on MAPKAPK2 / MAPK14

More from Aclaris Therapeutics

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT05216224
• ClinicalTrials.gov NCT06374459
• ClinicalTrials.gov NCT06648434

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACRS page.